Physician profile
Christopher Greer
NPI 1457379083
$1,654.96
in general payments reported to CMS, 2019-2025
12 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,249 · 2020: $60.82 · 2021: $45.59 · 2022: $209 · 2023: $90.30.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $90.30.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $90.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb, A Division of Bausch Health US, LLC | $1,032.55 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $290.39 | 2019-2023 | Trulance, Uceris |
| Takeda Pharmaceuticals U.S.A., INC. | $109.56 | 2020-2023 | Entyvio |
| Alcon Vision LLC | $78.58 | 2019-2022 | |
| Braintree Laboratories, INC. | $27.46 | 2019-2023 | Sutab |
| Regeneron Healthcare Solutions, INC. | $19.32 | 2023 | Dupixent |
| Biotissue Holdings INC. | $18.67 | 2022 | |
| Abbvie INC. | $18.65 | 2020 | |
| Eyevance Pharmaceuticals LLC | $16.34 | 2019 | |
| Sun Pharmaceutical Industries INC. | $16.34 | 2019 | |
| Bausch & Lomb Americas INC. | $15.37 | 2023 | Vyzulta |
| Neurocrine Biosciences, INC. | $11.73 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Greer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.